Breast cancer is among the frequently diagnosed cancers worldwide and is associated with a high mortality rate, especially when diagnosed late. Minimally invasive screening approaches based on an assessment of extracellular vesicle (EV)-encapsulating microRNA biomarkers have enabled earlier diagnosis and improved survival rates. Since field-effective transistors (FET) featuring complementary metal oxide semiconductor technology have been previously converted into highly sensitive biosensors, an integrated microfluidic system (IMS) was developed herein for quantifying concentrations of breast cancer biomarkers including microRNA-195 and microRNA-126. Following a (1) 4-h process in which 84% of the EVs were captured, (2) 20-min hybridization step in which 85 and 94% of the microRNA-195 and microRNA-126 were isolated, respectively, and (3) the DNA-FET biosensors could detect down to 84 and 75 aM concentrations of microRNA-195 and microRNA-126, respectively. The IMS automated the entire biomarker quantification process within 5 h, highlighting its potential as a sensitive platform for early-stage breast cancer diagnosis.

乳腺癌是世界范围内经常被诊断出的癌症之一，并且与高死亡率相关，尤其是在晚期诊断时。基于包裹细胞外囊泡（EV）的microRNA生物标记物评估的微创筛查方法已实现早期诊断并提高了生存率。由于具有互补金属氧化物半导体技术的场效应晶体管（FET）先前已被转换为高度敏感的生物传感器，因此本文开发了一种集成的微流控系统（IMS）来量化包括microRNA-195和microRNA-126在内的乳腺癌生物标记物的浓度。在（1）捕获了84％EV的4小时过程之后，（2）20分钟杂交步骤，其中分别分离了85％和94％的microRNA-195和microRNA-126，（3）DNA-FET生物传感器可以分别检测到84和75 aM浓度的microRNA-195和microRNA-126。IMS在5小时内自动完成了整个生物标志物定量过程，突出了其作为早期乳腺癌诊断的敏感平台的潜力。